As previously mentioned, the earliest studies that pre-dated clinical approval of these agents in ER+ MBC demonstrated that response was largely observed in ER+ vs. ER- breast cancers, suggesting that mutations in estrogen receptor (ESR) genes and others that play a role in ER signaling might lead to resistance. This evidence concerns the gene ESR1 and breast cancer.